Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: 50 mg of KX2-391 Ointment 1%
DRUG: 50 mg of KX2-391 Ointment 1%

Sponsor

Almirall, S.A.

Collaborators

[object Object]